NCT00420303

Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy and safety of Etanercept in patients with spondylarthropathy and refractory heel enthesitis.

Conditions

• Spondylarthropathies, Enthesitis

Interventions

Type	Name	Description
DRUG	Etanercept	50 mg injection once weekly
OTHER	Placebo	placebo

Timeline

• Start date: 2007-01-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2007-01-11
• Last updated: 2010-07-20
• Results posted: 2009-11-10

Locations

15 sites across 3 countries: France, Germany, Netherlands